新型冠状病毒感染抗病毒药物引起肝损伤的发生机制

曾雪; 李福青; 李清清; 王红

doi:10.12449/JCH240230

新型冠状病毒感染抗病毒药物引起肝损伤的发生机制

DOI: 10.12449/JCH240230

遵义医科大学附属医院消化内科，贵州遵义 563000

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：曾雪负责拟定写作思路，查找文献，分析资料，撰写文章；李福青、李清清参与收集资料，修改论文；王红负责选题，指导撰写文章，提供修改意见并最终定稿。

详细信息

通信作者:
王红， wanghong89zy@163.com （ORCID： 0000-0001-5411-3041）

计量
- 文章访问数: 396
- HTML全文浏览量: 188
- PDF下载量: 50
- 被引次数: 0
出版历程
- 收稿日期: 2023-06-16
- 录用日期: 2023-07-14
- 出版日期: 2024-02-19

Pathogenesis of liver injury caused by antiviral drugs for coronavirus disease 2019

Department of Gastroenterology，Affiliated Hospital of Zunyi Medical University，Zunyi，Guizhou 563000，China

More Information

Corresponding author: WANG Hong， wanghong89zy@163.com （ORCID： 0000-0001-5411-3041）

摘要

摘要: 药物性肝损伤是药物使用过程中因药物本身和/或其代谢产物，或由于特殊体质对药物的超敏感性或耐受性降低所导致。在近三年抗击新型冠状病毒感染（COVID-19）的诊治过程中，抗病毒药物起到了非常重要的作用，但国内外关于抗COVID-19药物引起肝损伤的报道较多，且其导致肝损伤的发生机制尚未明确。本文对COVID-19抗病毒药物的种类及其引起肝损伤机制的相关研究进展作一综述，旨在促进抗病毒药物的合理使用。
- 化学性与药物性肝损伤 /
- 新型冠状病毒 /
- 病理过程
Abstract: Drug-induced liver injury is caused by the drug itself and/or its metabolites during drug use or occurs due to hypersensitivity or reduced tolerance to the drug in a particular body type. In the last three years of the diagnosis and treatment of coronavirus disease 2019 （COVID-19）， antiviral drugs have played a very important role， but there are many reports on liver injury caused by anti-COVID-19 drugs in China and globally， with unknown pathogenesis of liver injury caused by such drugs. This article reviews the research advances in the types of antiviral drugs for COVID-19 and their mechanism in inducing liver injury， in order to promote the rational use of antiviral drugs.
- Chemical and Drug Induced Liver Injury /
- SARS-CoV-2 /
- Pathologic Processes

HTML全文

参考文献(50)

[1]	KAYAASLAN B, GUNER R. COVID-19 and the liver: A brief and core review[J]. World J Hepatol, 2021, 13( 12): 2013- 2023. DOI: 10.4254/wjh.v13.i12.2013.
[2]	CICHOŻ-LACH H, MICHALAK A. Liver injury in the era of COVID-19[J]. World J Gastroenterol, 2021, 27( 5): 377- 390. DOI: 10.3748/wjg.v27.i5.377.
[3]	CAI QX, HUANG DL, YU H, et al. COVID-19: Abnormal liver function tests[J]. J Hepatol, 2020, 73( 3): 566- 574. DOI: 10.1016/j.jhep.2020.04.006.
[4]	XIE YB, WANG SY, ZHANG C, et al. Research progress on the clinical features and mechanisms of COVID-19 combined with liver injury[J]. Chin J Hepatol, 2020, 28( 6): 523- 527. DOI: 10.3760/cma.j.cn501113-20200416-00190. 谢云波, 王嗣予, 张超, 等. 新型冠状病毒肺炎合并肝损伤的临床特征及其机制研究进展[J]. 中华肝脏病杂志, 2020, 28( 6): 523- 527. DOI: 10.3760/cma.j.cn501113-20200416-00190.
[5]	TANG HL, ZHOU LY, LI XT, et al. Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: A disproportionality analysis of U.S. food and drug administration adverse event reporting system(FAERS) data[J]. Int J Clin Pharm, 2021, 43( 4): 1116- 1122. DOI: 10.1007/s11096-021-01311-5.
[6]	SAVIANO A, WRENSCH F, GHANY MG, et al. Liver disease and coronavirus disease 2019: From pathogenesis to clinical care[J]. Hepatology, 2021, 74( 2): 1088- 1100. DOI: 10.1002/hep.31684.
[7]	OLRY A, MEUNIER L, DÉLIRE B, et al. Drug-induced liver injury and COVID-19 infection: The rules remain the same[J]. Drug Saf, 2020, 43( 7): 615- 617. DOI: 10.1007/s40264-020-00954-z.
[8]	SAHA L, VIJ S, RAWAT K. Liver injury induced by COVID 19 treatment- what do we know?[J]. World J Gastroenterol, 2022, 28( 45): 6314- 6327. DOI: 10.3748/wjg.v28.i45.6314.
[9]	LEI F, LIU YM, ZHOU F, et al. Longitudinal association between markers of liver injury and mortality in COVID-19 in China[J]. Hepatology, 2020, 72( 2): 389- 398. DOI: 10.1002/hep.31301.
[10]	Chinese Medical Association, Journal of Chinese Medical Association, Gastroenterology Branch of Chinese Medical Association, et al. Guideline for primary care of drug-induced liver injury(2019)[J]. Chin J Gen Pract, 2020, 19( 10): 868- 875. DOI: 10.3760/cma.j.cn114798-20200812-00900. 中华医学会, 中华医学会杂志社, 中华医学会消化病学分会, 等. 药物性肝损伤基层诊疗指南(2019年)[J]. 中华全科医师杂志, 2020, 19( 10): 868- 875. DOI: 10.3760/cma.j.cn114798-20200812-00900.
[11]	LAI RT, XIE Q. Clinical features of drug-induced liver failure and related diagnosis and treatment strategies[J]. J Clin Hepatol, 2021, 37( 11): 2534- 2538. DOI: 10.3969/j.issn.1001-5256.2021.11.006. 赖荣陶, 谢青. 药物性肝衰竭的临床特点及诊治策略[J]. 临床肝胆病杂志, 2021, 37( 11): 2534- 2538. DOI: 10.3969/j.issn.1001-5256.2021.11.006.
[12]	ASHOUR NA, ELMAATY A ABO, SARHAN AA, et al. A systematic review of the global intervention for SARS-CoV-2 combating: From drugs repurposing to molnupiravir approval[J]. Drug Des Devel Ther, 2022, 16: 685- 715. DOI: 10.2147/DDDT.S354841.
[13]	Department of Health, Chinese Medicine Bureau. Notice on the issuance of the new coronavirus infection diagnosis and treatment program(Trial 10th edition)[Z]. 2023. 中医药局综合司卫. 关于印发新型冠状病毒感染诊疗方案(试行第十版)的通知[Z]. 2023.
[14]	National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: Clinical and reaseach information on drug-induced liver injury[EB/OL].[ 2023-11-10]. https. www.ncbi.nlm, nih. gov/books/. https
[15]	The State Food and Drug Administration approved the import registration of the combined packaging of Pfizer Covid-19 therapeutic drug Nimatvir tablets and Ritonavir tablets with emergency conditions[J]. China Health Nutrition, 2022, 32( 5): Insert 5. 国家药监局应急附条件批准辉瑞公司新冠病毒治疗药物奈玛特韦片/利托那韦片组合包装进口注册[J]. 中国保健营养, 2022, 32( 5): 前插5.
[16]	KANG CK, SEONG MW, CHOI SJ, et al. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses[J]. Korean J Intern Med, 2020, 35( 4): 782- 787. DOI: 10.3904/kjim.2020.157.
[17]	ZAONGO SD, OUYANG J, CHEN YL, et al. HIV infection predisposes to increased chances of HBV infection: Current understanding of the mechanisms favoring HBV infection at each clinical stage of HIV infection[J]. Front Immunol, 2022, 13: 853346. DOI: 10.3389/fimmu.2022.853346.
[18]	KASPAR MB, STERLING RK. Mechanisms of liver disease in patients infected with HIV[J]. BMJ Open Gastroenterol, 2017, 4( 1): e000166. DOI: 10.1136/bmjgast-2017-000166.
[19]	VILLANUEVA-PAZ M, MORÁN L, LÓPEZ-ALCÁNTARA N, et al. Oxidative stress in drug-induced liver injury(DILI): From mechanisms to biomarkers for use in clinical practice[J]. Antioxidants(Basel), 2021, 10( 3): 390. DOI: 10.3390/antiox10030390.
[20]	LI XC, WANG WT, YAN SY, et al. Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management[J]. Front Pharmacol, 2022, 13: 1019487. DOI: 10.3389/fphar.2022.1019487.
[21]	KAO E, SHINOHARA M, FENG M, et al. Human immunodeficiency virus protease inhibitors modulate Ca²⁺ homeostasis and potentiate alcoholic stress and injury in mice and primary mouse and human hepatocytes[J]. Hepatology, 2012, 56( 2): 594- 604. DOI: 10.1002/hep.25702.
[22]	ZHANG R, WU YN, HAN XX, et al. Research of anti-HIV drug-related liver injury[J]. Chin J Gastroenterol Hepatol, 2021, 30( 5): 490- 495. DOI: 10.3969/j.issn.1006-5709.2021.05.003. 张瑞, 吴苑妮, 韩晓旭, 等. 抗艾滋病病毒药物相关性肝损伤的研究[J]. 胃肠病学和肝病学杂志, 2021, 30( 5): 490- 495. DOI: 10.3969/j.issn.1006-5709.2021.05.003.
[23]	HU DH, LIU LM, XIA HM. Study on the damage of human immunodeficiency virus protease inhibitor to human hepatocytes and the mechanism of intracellular calcium homeostasis regulation[J]. Chin J Infect Dis, 2014, 32( 9): 559- 561. DOI: 10.3760/cma.j.issn.1000-6680.2014.09.014. 胡东辉, 刘黎明, 夏红梅. 人类免疫缺陷病毒蛋白酶抑制剂对人肝细胞损伤及细胞内钙离子稳态调节机制研究[J]. 中华传染病杂志, 2014, 32( 9): 559- 561. DOI: 10.3760/cma.j.issn.1000-6680.2014.09.014.
[24]	FOUFELLE F, FROMENTY B. Role of endoplasmic reticulum stress in drug-induced toxicity[J]. Pharmacol Res Perspect, 2016, 4( 1): e00211. DOI: 10.1002/prp2.211.
[25]	NÚÑEZ M. Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management[J]. J Hepatol, 2006, 44( 1 Suppl): S132- S139. DOI: 10.1016/j.jhep.2005.11.027.
[26]	NAIDOO K, HASSAN-MOOSA R, MLOTSHWA P, et al. High rates of drug-induced liver injury in people living with HIV coinfected with tuberculosis(TB) irrespective of antiretroviral therapy timing during antituberculosis treatment: Results from the starting antiretroviral therapy at three points in TB trial[J]. Clin Infect Dis, 2020, 70( 12): 2675- 2682. DOI: 10.1093/cid/ciz732.
[27]	YU YC, CHEN CW. Pathogenesis of drug-induced liver injury: Current understanding and future needs[J]. J Clin Hepatol, 2021, 37( 11): 2515- 2524. DOI: 10.3969/j.issn.1001-5256.2021.11.003. 于乐成, 陈成伟. 药物性肝损伤的发生机制: 当前认识和未来需求[J]. 临床肝胆病杂志, 2021, 37( 11): 2515- 2524. DOI: 10.3969/j.issn.1001-5256.2021.11.003.
[28]	BOECKMANS J, RODRIGUES RM, DEMUYSER T, et al. COVID-19 and drug-induced liver injury: A problem of plenty or a petty point?[J]. Arch Toxicol, 2020, 94( 4): 1367- 1369. DOI: 10.1007/s00204-020-02734-1.
[29]	DROŻDŻAL S, ROSIK J, LECHOWICZ K, et al. An update on drugs with therapeutic potential for SARS-CoV-2(COVID-19) treatment[J]. Drug Resist Updat, 2021, 59: 100794. DOI: 10.1016/j.drup.2021.100794.
[30]	WANG Z, LIU HS, WANG XY. Drug interaction and clinical medication guidance of nirmatrelvir/ritonavir tablets[J]. Clin Med J, 2023, 21( 1): 21- 26. DOI: 10.3969/j.issn.1672-3384.2023.01.004. 王钊, 刘鹤松, 王秀云. 奈玛特韦片/利托那韦片药物相互作用与用药指导[J]. 临床药物治疗杂志, 2023, 21( 1): 21- 26. DOI: 10.3969/j.issn.1672-3384.2023.01.004.
[31]	PRUIJSSERS AJ, DENISON MR. Nucleoside analogues for the treatment of coronavirus infections[J]. Curr Opin Virol, 2019, 35: 57- 62. DOI: 10.1016/j.coviro.2019.04.002.
[32]	Expert group of“Expert consensus on the application of azvudine tablets in the treatment of novel coronavirus infection”. Expert consensus on the application of azvudine tablets in the treatment of novel coronavirus infection[J]. China Pharm, 2023, 32( 3): 1- 6. DOI: 10.3969/j.issn.1006-4931.2023.03.001. 《阿兹夫定片在新型冠状病毒感染救治中应用的专家共识》专家组. 阿兹夫定片在新型冠状病毒感染救治中应用的专家共识[J]. 中国药业, 2023, 32( 3): 1- 6. DOI: 10.3969/j.issn.1006-4931.2023.03.001.
[33]	JIANG JD. Study on azvudine, a new anti-covid-19 drug[J]. Chin J Med Guide, 2022, 24( 10): 947- 948. DOI: 10.3969/j.issn.1009-0959.2022.10.001. 蒋建东. 抗新冠病毒新药阿兹夫定研究[J]. 中国医药导刊, 2022, 24( 10): 947- 948. DOI: 10.3969/j.issn.1009-0959.2022.10.001.
[34]	National Institutes of Health. Coronavirus Disease 2019(COVID-19) treatment guidelines[EB/OL].( 2021-04-21)[ 2022-09-26]. https://www.covid19treatmentguidelines.nih.gov. https://www.covid19treatmentguidelines.nih.gov
[35]	AGRAWAL U, RAJU R, UDWADIA ZF. Favipiravir: A new and emerging antiviral option in COVID-19[J]. Med J Armed Forces India, 2020, 76( 4): 370- 376. DOI: 10.1016/j.mjafi.2020.08.004.
[36]	PILKINGTON V, PEPPERRELL T, HILL A. A review of the safety of favipiravir- a potential treatment in the COVID-19 pandemic?[J]. J Virus Erad, 2020, 6( 2): 45- 51. DOI: 10.1016/S2055-6640(20)30016-9.
[37]	LIANG Q, ZENG J, WU J, et al. Nucleoside reverse transcriptase inhibitors induced hepatocellular mitochondrial DNA lesions and compensatory enhancement of mitochondrial function and DNA repair[J]. Int J Antimicrob Agents, 2018, 51( 3): 385- 392. DOI: 10.1016/j.ijantimicag.2017.08.017.
[38]	ZHANG YL, WANG BS, LIANG Q, et al. Mitochondrial DNA D-loop AG/TC transition mutation in cortical neurons of mice after long-term exposure to nucleoside analogues[J]. J Neurovirol, 2015, 21( 5): 500- 507. DOI: 10.1007/s13365-015-0347-x.
[39]	LEE H, HANES J, JOHNSON KA. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase[J]. Biochemistry, 2003, 42( 50): 14711- 14719. DOI: 10.1021/bi035596s.
[40]	CAROTHERS C, BIRRER K, VO M. Acetylcysteine for the treatment of suspected remdesivir-associated acute liver failure in COVID-19: A case series[J]. Pharmacotherapy, 2020, 40( 11): 1166- 1171. DOI: 10.1002/phar.2464.
[41]	GERAGHTY RJ, ALIOTA MT, BONNAC LF. Broad-spectrum antiviral strategies and nucleoside analogues[J]. Viruses, 2021, 13( 4): 667. DOI: 10.3390/v13040667.
[42]	WANG BX, FISH EN. Global virus outbreaks: Interferons as 1st responders[J]. Semin Immunol, 2019, 43: 101300. DOI: 10.1016/j.smim.2019.101300.
[43]	YANG YZ, YIN JZ, ZHU WY. Research progress on the interaction between interferon and virus[J]. Chin J Exp Clin Virol, 2014, 28( 1): 79- 80, Cover 3. DOI: 10.3760/cma.j.issn.1003-9279.2014.01.027. 杨蕴芝, 殷建忠, 朱武洋. 干扰素与病毒相互作用的研究进展[J]. 中华实验和临床病毒学杂志, 2014, 28( 1): 79- 80, 封 3. DOI: 10.3760/cma.j.issn.1003-9279.2014.01.027.
[44]	ZHANG RZ, WANG Q, YANG JS. Impact of liver functions by repurposed drugs for COVID-19 treatment[J]. J Clin Transl Hepatol, 2022, 10( 4): 748- 756. DOI: 10.14218/JCTH.2021.00368.
[45]	YANG P, XU KJ, KONG LM, et al. Liver injury caused by antiviral agents for COVID-19[J]. Chin J Clin Infect Dis, 2020, 13( 2): 102- 108. DOI: 10.3760/cma.j.issn.1674-2397.2020.02.004. 阳平, 徐凯进, 孔丽敏, 等. 新型冠状病毒肺炎治疗中抗病毒药物引起的肝损伤[J]. 中华临床感染病杂志, 2020, 13( 2): 102- 108. DOI: 10.3760/cma.j.issn.1674-2397.2020.02.004.
[46]	WOOD DA, ALEEM A, DAVIS D. Providing access to monoclonal antibody treatment of coronavirus(COVID-19) patients in rural and underserved areas[EB/OL].( 2023-01-25)[ 2023-01-25]. https://www.ncbi.nlm.nih.gov/books/NBK574538. https://www.ncbi.nlm.nih.gov/books/NBK574538
[47]	SHAN SS, WANG RK, ZHANG Q, et al. China’s first approved novel neutralizing antibody combination therapy against SARS-cov-2—BRII-196/BRII-198[J]. Chin J Med Guide, 2022, 24( 1): 2- 8. DOI: 10.3969/j.issn.1009-0959.2022.01.001. 单思思, 王若珂, 张绮, 等. 安巴韦单抗注射液(BRII-196)及罗米司韦单抗注射液(BRII-198)——中国首个自主知识产权新冠病毒中和抗体联合治疗药物[J]. 中国医药导刊, 2022, 24( 1): 2- 8. DOI: 10.3969/j.issn.1009-0959.2022.01.001.
[48]	ALEEM A, VAQAR S. Monoclonal antibody therapy for high-risk coronavirus(COVID 19) patients with mild to moderate disease presentations[EB/OL].( 2023-02-05)[ 2023-02-05]. https://www.ncbi.nlm.nih.gov/books/NBK570603/ https://www.ncbi.nlm.nih.gov/books/NBK570603/
[49]	CONTI P, PREGLIASCO FE, CALVISI V, et al. Monoclonal antibody therapy in COVID-19[J]. J Biol Regul Homeost Agents, 2021, 35( 2): 423- 427. DOI: 10.23812/Conti_Edit_35_2_1.
[50]	ALEEM A, OLAREWAJU O, POZUN A. Evaluating and referring patients for outpatient monoclonal antibody therapy for coronavirus(COVID-19) in the emergency department[EB/OL].( 2023-01-25)[ 2023-01-25]. https://www.ncbi.nlm.nih.gov/books/NBK574561/. https://www.ncbi.nlm.nih.gov/books/NBK574561/